
KMB cuts its 2026 outlook as China diaper disruption weighs on growth, while productivity and volume-mix gains offer some support.
Kimberly-Clark Corporation is an American multinational personal care corporation that produces mostly paper-based consumer products. The company manufactures sanitary paper products and surgical & medical instruments. Kimberly-Clark brand name products include Kleenex facial tissue, Kotex feminine hygiene products, Cottonelle, Scott and Andrex toilet paper, Wypall utility wipes, KimWipes scientific cleaning wipes and Huggies disposable diapers and baby wipes.
| Revenue (TTM) | $16.58B |
| Gross Profit (TTM) | $6.24B |
| EBITDA | $3.48B |
| Operating Margin | 19.00% |
| Return on Equity | 104.90% |
| Return on Assets | 10.20% |
| Revenue/Share (TTM) | $49.95 |
| Book Value | $5.26 |
| Price-to-Book | 20.98 |
| Price-to-Sales (TTM) | 2.16 |
| EV/Revenue | 2.549 |
| EV/EBITDA | 13.21 |
| Quarterly Earnings Growth (YoY) | -32.30% |
| Quarterly Revenue Growth (YoY) | 0.60% |
| Shares Outstanding | $331.94M |
| Float | $331.31M |
| % Insiders | 0.71% |
| % Institutions | 99.25% |
Volatility is currently expanding

KMB cuts its 2026 outlook as China diaper disruption weighs on growth, while productivity and volume-mix gains offer some support.

KMB's 11.7% three-month gain reflects stronger productivity and volume-mix trends, but China and slower growth remain risks.

KMB's valuation discount and productivity gains support the case, but China disruption and slower category growth cloud its outlook.

Accomplished legal executive and global litigator brings proven track record of enterprise risk management and strategic leadership to support Kimberly-Clark's next chapter of growth DALLAS, Aug. 13, 2026 /PRNewswire/ -- Kimberly-Clark Corporation (NASDAQ: KMB) today announced the appointment of Suzana Blades as Senior Vice President and General Counsel, effective September 1, 2026. She will report to Jeff Melucci, Chief Strategy, Business Development and Administrative Officer, and will become a member of Kimberly-Clark's Executive Leadership Team.

Despite cost pressures and spending volatility, CL, KMB, CHD and BJ are using strategic initiatives and operational efficiencies to drive growth.

Kimberly-Clark is rated Buy, supported by a strong innovation pipeline, international growth, and upside from the Kenvue acquisition. KMB faces transient headwinds in North America and China, but these are expected to abate, with management forecasting mid- to high-single-digit EPS CAGR from 2026–2028. The Kenvue deal will initially dilute EPS, but synergy realization is tracking ahead of plan, with $1.9B cost and $1.4B revenue synergy targets.

Kimberly-Clark cuts its 2026 outlook as China diaper weakness, softer categories and North American shipment volatility pressure sales despite solid productivity.

Kimberly-Clark remains a compelling value and income play, supported by strong brands and resilient consumer demand. KMB trades at a discounted 14.6x forward P/E with a well-covered 4.7% dividend yield and an "A" credit rating. Near-term headwinds include a China diaper controversy and Kenvue integration, but these risks appear priced in.

Kimberly-Clark Corporation (KMB) Q2 2026 Earnings Call Prepared Remarks Transcript

Kimberly-Clark Corporation (KMB) Q2 2026 Earnings Call Transcript
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on KMB and any ticker you trade — then tracks every position and per-strategy win rate.